Tadashi Namisaki Selected Research

CDAA (Randox)

10/2022	Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis.
12/2021	Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats.
6/2019	Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
11/2017	Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development.
10/2016	DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis.
3/2015	Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
11/2013	Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.
7/2013	Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis.
5/2009	Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.
11/2007	Crosstalk between high-molecular-weight adiponectin and T-cadherin during liver fibrosis development in rats.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tadashi Namisaki Research Topics

Disease

50	Liver Cirrhosis (Hepatic Cirrhosis) 10/2022 - 10/2002
40	Fibrosis (Cirrhosis) 10/2022 - 10/2002
28	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 09/2003
24	Neoplasms (Cancer) 01/2021 - 06/2003
16	Fatty Liver 10/2022 - 10/2006
11	Non-alcoholic Fatty Liver Disease 11/2021 - 10/2006
10	Alcoholic Fatty Liver 10/2022 - 07/2008
8	Liver Diseases (Liver Disease) 10/2021 - 01/2009
8	Insulin Resistance 08/2020 - 01/2009
8	Carcinogenesis 03/2020 - 07/2003
7	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2021 - 01/2017
5	Hyperammonemia 08/2022 - 12/2017
5	Hepatic Encephalopathy 12/2021 - 12/2017
4	Sarcopenia 08/2022 - 01/2020
4	Alcoholic Liver Diseases (Alcoholic Liver Disease) 12/2021 - 01/2013
4	Inflammation (Inflammations) 12/2021 - 01/2013
4	Infections 06/2021 - 01/2017
3	Ascites 05/2022 - 08/2017
3	Thrombophilia 03/2022 - 05/2019
3	Liver Neoplasms (Liver Cancer) 01/2021 - 12/2014
3	Muscle Cramp (Cramp) 12/2020 - 01/2019
2	Atrophy 08/2022 - 12/2021
2	Pancreatic Neoplasms (Pancreatic Cancer) 05/2022 - 08/2009
2	Acute-On-Chronic Liver Failure 04/2022 - 05/2020
2	Cholangitis 10/2021 - 02/2018
2	Alcoholic Liver Cirrhosis (Alcoholic Cirrhosis) 09/2021 - 07/2021
2	Cognitive Dysfunction 06/2021 - 03/2020
2	Dysbiosis 06/2021 - 01/2019
2	Body Weight (Weight, Body) 01/2021 - 08/2017
2	Fatigue 12/2020 - 01/2018
2	Cholangiocarcinoma 10/2020 - 10/2018
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2020 - 01/2019
2	Hemorrhage 09/2020 - 01/2017

Drug/Important Bio-Agent (IBA)

16	Amino Acids FDA Link 10/2022 - 07/2003
14	Choline (Choline Chloride)IBA 10/2022 - 07/2003
13	EndotoxinsIBA 05/2022 - 01/2013
13	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2019 - 12/2003
11	CDAA (Randox)IBA 10/2022 - 07/2003
10	Biomarkers (Surrogate Marker)IBA 04/2022 - 07/2003
8	LipopolysaccharidesIBA 10/2022 - 08/2017
8	CytokinesIBA 08/2022 - 05/2006
8	Losartan (Cozaar)FDA LinkGeneric 01/2022 - 05/2009
8	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 08/2010 - 12/2003
7	von Willebrand FactorIBA 04/2022 - 02/2018
7	Angiotensin II Type 1 Receptor BlockersIBA 01/2022 - 05/2009
7	Angiotensin IIIBA 12/2021 - 09/2003
7	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2021 - 02/2016
7	CollagenIBA 10/2020 - 12/2008
7	Glutathione Transferase (Glutathione S-Transferase)IBA 06/2018 - 07/2003
6	Rifaximin (L 105)FDA Link 10/2022 - 12/2017
6	Proteins (Proteins, Gene)FDA Link 06/2021 - 10/2002
6	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 04/2010 - 12/2003
5	Toll-Like Receptor 4IBA 10/2022 - 06/2019
5	EnzymesIBA 04/2022 - 07/2003
5	Branched-Chain Amino AcidsIBA 12/2021 - 01/2009
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2021 - 09/2017
5	Messenger RNA (mRNA)IBA 01/2021 - 10/2002
5	Glucose (Dextrose)FDA LinkGeneric 03/2020 - 11/2017
4	Carbon Tetrachloride (Tetrachloromethane)IBA 12/2021 - 01/2017
4	Anti-Bacterial Agents (Antibiotics)IBA 12/2021 - 03/2015
4	Angiotensin Receptor AntagonistsIBA 12/2021 - 10/2014
4	Carrier Proteins (Binding Protein)IBA 10/2021 - 09/2017
4	Antiviral Agents (Antivirals)IBA 08/2020 - 01/2017
4	Sorafenib (BAY 43-9006)FDA Link 12/2019 - 10/2014
4	AldosteroneIBA 08/2017 - 05/2010
4	Pharmaceutical PreparationsIBA 12/2014 - 02/2007
3	Tolvaptan FDA Link 05/2022 - 08/2017
3	AntigensIBA 04/2022 - 12/2020
3	ZincIBA 03/2022 - 06/2021
3	lenvatinibIBA 01/2022 - 01/2021
3	AlbuminsIBA 10/2021 - 01/2017
3	Tissue Inhibitor of MetalloproteinasesIBA 10/2021 - 08/2020
3	Hyaluronic Acid (Hyaluronan)IBA 10/2021 - 08/2020
3	Matrix Metalloproteinases (MMPs)IBA 06/2021 - 10/2002
3	AntioxidantsIBA 06/2021 - 12/2020
3	DiureticsIBA 01/2021 - 08/2017
3	Therapeutic UsesIBA 12/2020 - 01/2008
3	Insulin (Novolin)FDA Link 04/2020 - 02/2016
3	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2019 - 02/2016
3	InterferonsIBA 09/2018 - 01/2008
3	Transforming Growth Factor beta (TGF-beta)IBA 12/2016 - 05/2006
3	Chelating AgentsIBA 06/2011 - 09/2003
3	Perindopril FDA LinkGeneric 05/2006 - 12/2003
3	Tissue Inhibitor of Metalloproteinase-1IBA 09/2003 - 10/2002
2	MyostatinIBA 08/2022 - 03/2022
2	AmmoniaIBA 03/2022 - 03/2020
2	Ethanol (Ethyl Alcohol)IBA 12/2021 - 01/2021
2	Collagen Type III (Type III Collagen)IBA 10/2021 - 08/2020
2	Collagen Type IV (Type IV Collagen)IBA 10/2021 - 02/2016
2	Triglycerides (Triacylglycerol)IBA 09/2021 - 06/2020
2	Interleukin-8 (Interleukin 8)IBA 06/2021 - 07/2005
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 07/2008
2	Carnitine (L-Carnitine)FDA LinkGeneric 12/2020 - 01/2019
2	procollagen Type III-N-terminal peptide (PIIP)IBA 10/2020 - 08/2020
2	Gemcitabine FDA Link 10/2020 - 08/2009

Therapy/Procedure

17	Therapeutics 05/2022 - 02/2005
8	Oral Administration 10/2022 - 05/2005
7	Drug Therapy (Chemotherapy) 12/2020 - 12/2014
4	Chemoprevention 10/2014 - 05/2005
3	Intraperitoneal Injections 01/2021 - 01/2019